NO20015396L - Use of soluble costimulatory molecules to enhance immune responses - Google Patents

Use of soluble costimulatory molecules to enhance immune responses

Info

Publication number
NO20015396L
NO20015396L NO20015396A NO20015396A NO20015396L NO 20015396 L NO20015396 L NO 20015396L NO 20015396 A NO20015396 A NO 20015396A NO 20015396 A NO20015396 A NO 20015396A NO 20015396 L NO20015396 L NO 20015396L
Authority
NO
Norway
Prior art keywords
immune responses
costimulatory molecules
enhance immune
soluble costimulatory
soluble
Prior art date
Application number
NO20015396A
Other languages
Norwegian (no)
Other versions
NO20015396D0 (en
Inventor
Knut Sturmhoefel
Stanley F Wolf
Margot O'toole
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of NO20015396D0 publication Critical patent/NO20015396D0/en
Publication of NO20015396L publication Critical patent/NO20015396L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
NO20015396A 1999-05-06 2001-11-05 Use of soluble costimulatory molecules to enhance immune responses NO20015396L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13294499P 1999-05-06 1999-05-06
PCT/US2000/012435 WO2000067788A2 (en) 1999-05-06 2000-05-05 Use of soluble costimulatory molecules to enhance immune responses

Publications (2)

Publication Number Publication Date
NO20015396D0 NO20015396D0 (en) 2001-11-05
NO20015396L true NO20015396L (en) 2002-01-02

Family

ID=22456295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015396A NO20015396L (en) 1999-05-06 2001-11-05 Use of soluble costimulatory molecules to enhance immune responses

Country Status (15)

Country Link
EP (1) EP1181053A2 (en)
JP (1) JP2002544170A (en)
KR (1) KR20020001865A (en)
CN (1) CN1377279A (en)
AU (1) AU4825700A (en)
BR (1) BR0010711A (en)
CA (1) CA2373256A1 (en)
CZ (1) CZ20013964A3 (en)
HK (1) HK1041810A1 (en)
HU (1) HUP0201222A3 (en)
IL (1) IL146106A0 (en)
NO (1) NO20015396L (en)
PL (1) PL360915A1 (en)
WO (1) WO2000067788A2 (en)
ZA (1) ZA200109376B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3521382B2 (en) 1997-02-27 2004-04-19 日本たばこ産業株式会社 Cell surface molecules that mediate cell-cell adhesion and signal transduction
JP4210454B2 (en) 2001-03-27 2009-01-21 日本たばこ産業株式会社 Inflammatory bowel disease treatment
JP3871503B2 (en) 1999-08-30 2007-01-24 日本たばこ産業株式会社 Immune disease treatment
JP3597140B2 (en) 2000-05-18 2004-12-02 日本たばこ産業株式会社 Human monoclonal antibody against costimulatory molecule AILIM and pharmaceutical use thereof
JP4212278B2 (en) 2001-03-01 2009-01-21 日本たばこ産業株式会社 Graft rejection inhibitor
EP1910387B1 (en) * 2005-06-30 2016-11-16 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
EP1973573B1 (en) 2005-12-08 2013-05-22 University of Louisville Research Foundation, Inc. Methods and compositions for expanding t regulatory cells
JP5564181B2 (en) * 2005-12-08 2014-07-30 シルワン，ハヴァル Immune stimulating compositions and methods
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
JP2014521687A (en) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US20150056232A1 (en) * 2012-04-02 2015-02-26 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
PT3065771T (en) 2013-11-04 2019-06-24 Uti Lp Methods and compositions for sustained immunotherapy
WO2016198932A2 (en) 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CN110743006B (en) * 2019-11-22 2020-08-25 北京启辰生生物科技有限公司 Composition for synergistically relieving immune cell failure and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE251181T1 (en) * 1998-07-28 2003-10-15 Micromet Ag HETEROMINI BODY

Also Published As

Publication number Publication date
WO2000067788A3 (en) 2001-04-05
NO20015396D0 (en) 2001-11-05
HUP0201222A2 (en) 2002-08-28
KR20020001865A (en) 2002-01-09
ZA200109376B (en) 2003-03-13
HK1041810A1 (en) 2002-07-26
CZ20013964A3 (en) 2002-06-12
CA2373256A1 (en) 2000-11-16
HUP0201222A3 (en) 2004-07-28
WO2000067788A2 (en) 2000-11-16
JP2002544170A (en) 2002-12-24
CN1377279A (en) 2002-10-30
IL146106A0 (en) 2002-07-25
PL360915A1 (en) 2004-09-20
EP1181053A2 (en) 2002-02-27
BR0010711A (en) 2002-02-13
AU4825700A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
NO20015396D0 (en) Use of soluble costimulatory molecules to enhance immune responses
NO20034693D0 (en) Use of follistatin to increase muscle mass
NO20004133D0 (en) Antibodies to human CD40
NO20020799D0 (en) Device for extracting a substance for the preparation of a drink
NO20012312L (en) Infrared imaging to detect components of hygiene items
HK1061403A1 (en) ANTIBODIES TO HUMAN IL-1ß
FR2751223B1 (en) FELIN POLYNUCLEOTIDE VACCINE FORMULA
DE60036968D1 (en) Adamantane derivatives for the treatment of inflammatory, immunological and cardiovascular diseases
HUP0301477A3 (en) Antibodies to human mcp-1 molecule
NO20020779D0 (en) Methods, preparations and kits to promote healing of central nervous system damage
EE04747B1 (en) Process for the preparation of amine-platinum complexes
NO20015227D0 (en) Steps to increase the effectiveness of anti-cancer agents
ID26441A (en) PROCESS TO PRODUCE ANHYDRIDAL FTALATES
NO20015542L (en) Process for the preparation and use of N-desmethylzopiclones
NO20021159L (en) Method of interferometric processing to identify layer boundaries
NO20003358D0 (en) Connecting device for interconnection of two objects
ID30308A (en) ELECTRONIC APARATUS EASY TO BRING
AU2086501A (en) Inducing cellular immune responses to carcinoembryonic antigen using peptide andnucleic acid compositions
IS6381A (en) Novelty in the use of antibodies in vaccines
ATE241622T1 (en) THIAZOLIDINDONE DERIVATIVES AS ANTIDIABETICS
ID28435A (en) KITCHEN CLEANER TOWELS AND METHODS TO PRODUCE IT
AU2002249917A1 (en) Induction of immune responses to isoaspartyl-modified antigens
AU5801398A (en) The use of cd4-binding small molecules to inhibit immune responses
AU6019599A (en) Use of mcrp to enhance immune responses
NO20011412D0 (en) Methods for down-modulating the immune response to therapeutic proteins

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application